News
Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback